DXCM Chart

1 Month

	Date	Diff
	2025-05-05	-1.65 %
DexCom (DXCM) stock fell by 1.65% following mixed financial results, including a slight earnings miss and a downward adjustment of gross margin forecasts despite strong sales and a new share buyback program; concerns about the company being overvalued and risks from increasing competition in the diabetes market also contributed to the decline. DexCom (NASDAQ:DXCM) stock fell 1.65% despite receiving a target price upgrade from Canaccord Genuity because the company reported earnings that missed consensus estimates, with a quarterly EPS of $0.32 compared to the expected $0.33. DexCom (DXCM) stock fell by 1.65% following Piper Sandler's downgrade of its price target from $100.00 to $90.00, despite the company reporting revenue growth; the downgrade likely reflects concerns over recent earnings that fell short of consensus estimates and the performance of the stock amid various analysts' mixed ratings.
	2025-04-29	+0.17 %
DexCom (DXCM) stock rose by 0.17% following expectations of a solid earnings report, with analysts forecasting earnings of $0.33 per share and revenues of $1.02 billion for Q1 2025. Dexcom (DXCM) stock rose by 0.17% ahead of its upcoming earnings report, which historically tends to cause significant volatility due to investor sentiment and market reactions to earnings announcements. The stock's rise may be attributed to positive earnings expectations, with forecasted earnings per share of $0.33 on revenues of $1.02 billion, indicating potential growth compared to the previous year's performance.
	2025-04-28	-0.67 %
DexCom Inc. (NASDAQ: DXCM) experienced a 0.67% decline last night, amidst a recent positive short-term trend but a significant 44.07% drop over the past year, possibly reflecting concerns about its long-term performance despite recent gains.
	2025-04-22	+0.33 %
DexCom (NASDAQ: DXCM) stock rose by 0.33% amid an ongoing investigation by Johnson Fistel, PLLP into potential breaches of fiduciary duties and misleading statements made by the company's insiders. The stock's increase may be attributed to speculation that the investigation could lead to accountability and corrective measures that might stabilize investor confidence following its significant previous decline.
	2025-04-21	-3.59 %
Shares of DexCom, Inc. (NASDAQ:DXCM) fell by 3.59% due to a combination of insider selling activity, where executives sold significant portions of their stock, and a quarterly earnings report that missed analysts’ expectations, indicating potential underlying challenges for the company.
	2025-04-16	-0.72 %
Dexcom (DXCM) stock was down 0.72% largely due to concerns about potential tariffs on pharmaceuticals announced by the Trump administration, which are causing uncertainty in the healthcare sector and could impact manufacturing costs for medical devices. DexCom (DXCM) stock declined by 0.72% following an investigation launched by Johnson Fistel, PLLP, into potential fiduciary breaches and violations of securities laws by its board and executives, concerning misleading statements about the company's growth and market share.
	2025-04-10	+0.69 %
Dexcom (DXCM) stock rose 0.69% after the FDA approved its latest diabetes device for a longer 15-day wear period, boosting investor confidence in the company's innovation.
	2025-04-08	-1.53 %
DexCom, Inc. (NASDAQ:DXCM) stock fell by 1.53% due to insiders selling a significant number of shares and missing quarterly earnings expectations, which raised concerns among investors.
	2025-04-01	-1.42 %
DexCom (DXCM) stock decreased by -1.42% due to concerns over poor execution and fears of disruption from GLP-1 drugs, as highlighted in Sands Capital's Q4 2024 investor letter.
	2025-03-24	+2.06 %
DexCom (NASDAQ:DXCM) stock rose 2.06% after receiving a "Moderate Buy" consensus recommendation from analysts, with several firms raising their price targets and ratings, reflecting positive sentiment towards the company's growth prospects in the continuous glucose monitoring market.
	2025-03-20	+2.36 %
DexCom (DXCM) stock rose by 2.36% following reports that several institutional investors, including Independent Advisor Alliance, increased their stakes in the company, indicating strong confidence in its growth potential.
	2025-03-18	-0.91 %
DexCom (DXCM) stock fell by 0.91% likely due to significant reductions in its holdings by Wealthfront Advisers LLC and insider sales, alongside a quarterly earnings miss, which may have affected investor sentiment.
	2025-03-14	+3.23 %
DexCom (DXCM) stock rose 3.23% following PNC Financial Services Group Inc.'s substantial increase in its shareholding, along with upgrades and positive ratings from several brokerages, indicating heightened investor confidence in the company's potential for growth in the continuous glucose monitoring market.
	2025-03-13	-3.22 %
DexCom (DXCM) stock fell 3.22% as analysts at William Blair revised their Q1 2025 earnings estimates downward, projecting earnings per share of $0.33, down from a previous estimate of $0.34, which likely contributed to investor concerns.
	2025-03-12	+0.71 %
DexCom (DXCM) stock rose by 0.71% due to increased institutional investments, positive ratings upgrades from analysts, and a growing consensus among them that it is a strong buy, despite the company having recently reported earnings that slightly missed expectations. The increase in stock price can be attributed to institutional investors acquiring larger stakes and analysts raising their price targets and upgrading their ratings on the stock, indicating a bullish sentiment towards DexCom's future prospects.
	2025-03-11	-0.65 %
DexCom (NASDAQ:DXCM) stock declined by 0.65%, attributed to a combination of insider share sales, advisory changes among hedge funds, and a recent earnings report that fell short of analyst expectations.
	2025-03-10	-9.15 %
Dexcom (DXCM) stock dropped 9.15% to a four-month low due to a warning letter from the FDA related to inspections of two of its U.S. facilities, marking the company's sixth consecutive day of losses.
	2025-03-07	-2.1 %
DexCom (DXCM) stock fell 2.1% due to its recent quarterly earnings report showing earnings per share that missed analysts' expectations, along with insider selling and mixed ratings from investment analysts.
	2025-03-06	-2.99 %
DexCom (DXCM) stock declined by 2.99% despite Citigroup raising its price target from $101 to $104, likely due to a recent earnings miss and insider stock sales, which could have raised concerns among investors.
	2025-02-26	+1.8 %
DexCom (NASDAQ:DXCM) stock rose by 1.8% following increased institutional investments, including a 21.7% increase in holdings by Sanctuary Advisors LLC and several positive analyst ratings adjustments.
	2025-02-21	-0.63 %
DexCom Inc. (DXCM) stock fell by 0.63% due to a combination of missing earnings expectations and insider selling of shares, influencing investor sentiment negatively.
	2025-02-18	+1.64 %
DexCom (NASDAQ: DXCM) stock rose 1.64% due to increased institutional investments, with Van ECK Associates Corp significantly expanding its stake, alongside strategic upgrades from several equity research analysts who maintain positive outlooks for the company's performance. Dexcom (DXCM) stock rose by 1.64% due to an increase in Q1 2025 earnings per share estimates from Leerink Partners, along with positive ratings and target price adjustments from several other analysts, indicating strong investor confidence in the company's financial outlook.
	2025-02-14	+5.92 %
Dexcom (DXCM) stock rose 5.92% despite missing fourth-quarter profit expectations due to better-than-expected sales, reflecting strong demand for its continuous glucose monitors (CGMs) that provide real-time blood sugar monitoring.
	2025-02-13	+0.26 %
Dexcom (DXCM) stock rose by 0.26% last night, likely spurred by a positive market sentiment and overall advancements within the tech and healthcare sectors, including significant growth in related companies that could reflect favorably on Dexcom's market position and prospects. DexCom (DXCM) stock increased by 0.26% due to strong institutional ownership, solid revenue and earnings compared to competitors, and positive analyst sentiment regarding its future growth potential.
	2025-02-11	-2.14 %
DexCom, Inc. (DXCM) stock declined by 2.14% following a report that Bleakley Financial Group LLC reduced its stake in the company, along with several other institutional investors adjusting their positions, which may have contributed to investor concern regarding its stock performance. DexCom (DXCM) stock fell by 2.14% likely due to profit-taking following insider sales of shares by top executives and cautious anticipation ahead of their upcoming earnings report, where analysts expect moderate earnings growth.
	2025-02-10	+0.22 %
DexCom, Inc. (NASDAQ:DXCM) saw a slight stock increase of 0.22% following a series of adjustments in institutional investor holdings, where some boosted their positions in the company, indicating potential confidence in the stock's future performance.
	2025-02-06	-0.52 %
DexCom (DXCM) stock decreased by 0.52%, likely due to the increasing popularity of GLP-1 drugs, which may diminish the demand for its continuous glucose monitoring devices as more people focus on weight loss and reducing diabetes risk.
	2025-02-05	+1.51 %
DexCom, Inc. (NASDAQ:DXCM) saw its stock increase by 1.51% due to significant investments and stake increases by institutional investors, indicating strong confidence in the company's future prospects.
	2025-02-04	+0.47 %
DexCom (DXCM) stock rose 0.47% after Redburn Atlantic upgraded it from a neutral to a buy rating and increased its price target from $85.00 to $115.00, indicating positive sentiment from analysts about the company's future performance.
	2025-02-03	+0.25 %
Dexcom (DXCM) stock was up 0.25% last night, despite its substantial underperformance over the past year due to disappointing financial results, indicating potential investor optimism or market adjustments.
	2025-01-28	+0.94 %
DexCom (DXCM) stock rose by 0.94% as institutional holdings in the company increased, particularly with Fifth Third Bancorp raising its stake by 21.5%, indicating strong investor confidence in the medical device company. DexCom (DXCM) stock rose by 0.94% due to its stronger financial performance compared to Health Sciences Acquisitions Co. 2, highlighted by higher revenue, earnings, and a favorable consensus rating from analysts, which reflects confidence in its business prospects in the medical technology sector.
	2025-01-24	+1.2 %
DexCom (DXCM) stock rose by 1.2% following significant increases in institutional investments, with UMB Bank n.a. and other firms boosting their holdings in the fourth quarter, indicating strong investor confidence in the company's continuous glucose monitoring systems.
	2025-01-17	-0.54 %
DexCom (DXCM) stock has decreased by 0.54%, potentially due to recent fluctuations in hedge fund investments, mixed analyst ratings, and insider selling activity, despite some upgrades in price targets from brokerages.
	2025-01-15	+1.55 %
DexCom, Inc. (DXCM) stock increased by 1.55% after Harbor Capital Advisors Inc. reduced its stake in the company, while several other institutional investors have been actively buying and selling shares, indicating ongoing investor interest and positive analyst ratings that likely boosted confidence in the stock's future performance. DexCom, Inc. (DXCM) stock rose 1.55% following increased institutional investment, notably by the Czech National Bank which raised its holdings by 3.7% during the fourth quarter, indicating growing confidence in the company's performance.
	2024-12-27	-0.41 %
Dexcom (DXCM) stock fell by 0.41% amid a challenging environment for cloud software providers in 2024, largely due to macroeconomic pressures impacting customer spending. DexCom (DXCM) stock recently experienced a decline of 0.41%, attributed to its high valuation and a general trend where some expensive stocks underperformed in 2024, contrasting with more affordable counterparts that showed significant gains.
	2024-12-24	+0.88 %
Dexcom (DXCM) stock rose by 0.88% possibly due to market optimism and recovery after a period of significant declines, although the overall performance of digital health companies has been notably poor, reflecting a challenging environment in the sector. Dexcom (DXCM) stock rose by 0.88% amidst a challenging year for digital health companies, as it likely benefited from broader market trends and investor interest in healthcare-focused technology, despite its previous struggles.
	2024-12-20	+5.57 %
DexCom, Inc. (NASDAQ:DXCM) stock rose by 5.57% following positive analyst ratings and price target upgrades, despite some institutional investors reducing their stakes in the company.
	2024-12-19	+0.74 %
Dexcom (DXCM) stock rose by 0.74% last night, potentially driven by its participation in a $200 million funding round for the smart ring maker Oura, which indicates investor confidence in the company’s future prospects within the glucose monitoring and health tech space.
	2024-12-17	+1.82 %
DexCom, Inc. (NASDAQ:DXCM) stock rose 1.82% last night, bolstered by a consensus "Moderate Buy" rating from analysts, with multiple investment firms raising their price targets, indicating positive sentiment towards the company's growth potential and recent performance.
	2024-12-10	+1.28 %
DexCom (DXCM) stock increased by 1.28% due to favorable analyst ratings, a strong institutional ownership indicating long-term growth potential, and a significantly higher revenue and earnings compared to its competitor Nemaura Medical (NMRD).
	2024-12-09	+0.89 %
DexCom (DXCM) stock rose by 0.89% after a series of institutional investors adjusted their positions in the company, with analysts raising price targets and maintaining favorable ratings, indicating positive sentiment around the stock's potential for growth. The rise in DexCom's stock is attributed to increased analyst price targets, positive ratings from multiple analysts, and the overall investor sentiment surrounding institutional stake movements in the company.
	2024-12-02	+1.69 %
DexCom, Inc. (DXCM) stock rose by 1.69% due to significant increases in institutional investments, with major hedge funds boosting their stakes and positive analyst ratings suggesting a strong future for the company, particularly in light of its continuous glucose monitoring products. DexCom (NASDAQ: DXCM) stock rose by 1.69% despite the company facing challenges and year-to-date declines in share price due to slower-than-expected growth and unimpressive financial results. The recent increase in stock price may have been driven by market reactions to new developments or investor optimism despite the company's ongoing struggles.
	2024-11-26	+0.14 %
DexCom (DXCM) stock rose by 0.14% amidst various institutional investors modifying their holdings, with significant purchases from Canada Pension Plan Investment Board and Massachusetts Financial Services, indicating renewed confidence in the company’s growth potential despite recent reductions by other investors like PNC Financial Services Group. The stock's increase can be attributed to positive market sentiment driven by institutional investment activity and analyst ratings, suggesting a strong outlook for the company's continuous glucose monitoring systems. DexCom, Inc. (DXCM) saw a slight increase of 0.14% in its stock price recently, influenced by mixed activities from institutional investors including significant reductions in holdings by Raymond James Trust N.A. and increased investments by others, indicating fluctuating investor sentiments amid research analysts adjusting their price targets.
	2024-11-25	+6.87 %
DexCom, Inc. (NASDAQ: DXCM) stock surged 6.87% following reports of significant institutional trading activity, including sharp reductions and increases in stakes by various investors, as well as analyst rating adjustments favoring the stock. The increase in DexCom's stock price could be attributed to positive sentiment from institutional investors, indicating confidence in the company's growth potential, supported by recent analyst upgrades. DexCom, Inc. (DXCM) experienced a 6.87% stock increase, attributed to ongoing positive market sentiment following recent analyst upgrades and changes in institutional investor positions, despite some insider selling activities.
	2024-11-22	-2.19 %
DexCom (DXCM) stock fell by 2.19% amid ongoing fluctuations in share prices and a series of share transactions by company insiders, as well as a range of price target adjustments by analysts. The decline in DexCom's stock is attributed to recent price target reductions by several brokerages, alongside insider selling activity, which can signal weakening investor confidence or market sentiment. DexCom (DXCM) stock fell by 2.19% largely due to analysts downgrading the stock's ratings and reducing their price targets, reflecting a generally negative market sentiment despite some institutional investors increasing their positions in the company. DexCom, Inc. (NASDAQ:DXCM) stock experienced a decline of 2.19% following mixed analyst ratings and adjustments to target prices from various investment firms, which may reflect concerns about the company's future growth prospects and market performance.
	2024-11-19	-1.82 %
Dexcom (DXCM) stock experienced a decline of 1.82% after the Department of Health and Human Services' Office of Inspector General (HHS OIG) rated HHS's information security program as "not effective," which may indicate potential regulatory or operational challenges for companies like Dexcom that rely on secure data systems.
	2024-11-18	+0.51 %
DexCom, Inc. (DXCM) stock rose by 0.51% following mixed signals from institutional investors regarding their ownership stakes, with some hedge funds increasing their positions while others, like Atria Investments, reduced theirs, amid favorable price target updates from research analysts.
	2024-11-12	+5.73 %
DexCom (DXCM) stock rose 5.73% after significant increases in institutional ownership, with Van ECK Associates Corp increasing its stake by 14%, showing strong investor confidence in the company's future.
	2024-11-08	+1.52 %
DexCom (DXCM) shares rose by 1.52% despite a previous steep drop after disappointing quarterly earnings, possibly due to market corrections or positive investor sentiment in the wake of recent performance challenges.
	2024-11-06	-0.57 %
DexCom (NASDAQ:DXCM) shares fell by 0.57% after StockNews.com downgraded its rating from buy to hold, amidst various analyst price target adjustments, indicating mixed sentiments on the stock's future performance. The stock likely declined due to the downgrade in its rating by StockNews.com, which may have influenced investor sentiment negatively.